8-K Announcements
6Material company update
May 26, 2026·SEC
Material company update
May 14, 2026·SEC
Material company update
Apr 10, 2026·SEC
Leap Therapeutics faces a precarious outlook as its reliance on high-cost clinical development continues to erode its capital base without a corresponding commercial revenue stream. The company's reliance on external financing to sustain operations, evidenced ...
Price trend, volume and key moving averages
Trailing total returns as of 9/25/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Benchmark LPTX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Leap Therapeutics, Inc. (LPTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.77 | $64.53M | 10.99 | — | — | 5.11% | — | |
| $34.00 | $7.02B | -12.27 | — | -7585.86% | -69.59% | — | |
| $8.50 | $353.96M | -2500.00 | 10.37% | 69.76% | — | — | |
| $57.52 | $8.81B | 20.77 | 87.32% | 55.22% | 72.3% | — | |
| $25.06 | $3.15B | -7.62 | -4.26% | -386.32% | -87.98% | — | |
| $59.38 | $1.96B | -6.10 | -43.89% | -287.84% | -37.99% | — |
Leap Therapeutics, Inc. (LPTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Leap Therapeutics, Inc. (LPTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 26, 2026·SEC
May 14, 2026·SEC
Apr 10, 2026·SEC
Get notified when LPTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Leap Therapeutics, Inc. (LPTX) stock FAQ — growth, dividends, profitability & financials explained
Leap Therapeutics, Inc. (LPTX) reported $0.2M in revenue for fiscal year 2025.
Leap Therapeutics, Inc. (LPTX) reported a net loss of $56.9M for fiscal year 2025.
Leap Therapeutics, Inc. (LPTX) has a return on equity (ROE) of 5.1%. This is below average, suggesting room for improvement.
Leap Therapeutics, Inc. (LPTX) had negative free cash flow of $79.6M in fiscal year 2025, likely due to heavy capital investments.